CTOAM (Cancer Treatment Options & Management Inc.) was founded with the specific purpose of helping cancer patients access precision oncology services that reflect the unique molecular features of their cancer rather than a generalized treatment pathway. According to co-founder Michelle Morand, the organization was built around the most current research in cancer care, beginning with understanding what is happening at the molecular level, not simply following standardized protocols.
"From the earliest days, CTOAM focused on providing patients with advanced diagnostic insight, personalized research and treatment access that could support more informed decisions," Morand explains. "Many patients arrive after feeling uncertain about their options or sensing that additional answers may exist beyond what they have been offered by their Oncologist." CTOAM's role, from her perspective, is to help clarify those possibilities through a more thorough diagnosis and treatment access support.
